Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Viking Therapeutics completes enrollment in Phase 2 trial of VK2735
Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...
Morningstar4d
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.
Investor's Business Daily on MSN4d
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.
Nasdaq3d
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking also reiterated its plans to start a late-stage study on the subcutaneous version of VK2735 by the first half of this year. The obesity market has garnered much interest lately, as both ...